Clinical trial
Inductive Camrelizumab and Apatinib for Patients With Locally Advanced and Resectable Oral Squamous Cell Carcinoma: A Single-arm Phase I Trial
NCT04393506 is registered in ClinicalTrials.gov with Shanghai Jiao Tong University School of Medicine as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Inductive Camrelizumab and Apatinib for Patients With Locally Advanced and Resectable Oral Squamous Cell Carcinoma: A Single-arm Phase I Trial
- Lead sponsor
- Shanghai Jiao Tong University School of Medicine
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- April 23, 2020
- Completion date
- November 10, 2023
- Enrollment
- 21 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
inductive therapy, oral cancer, programmed cell death 1 inhibitor, vegfr2 inhibitor